Bone marrow scintigraphy in breast cancer

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Breast cancer management relies on accurate staging and monitoring of skeletal involvement.
• Conventional bone scintigraphy (CBS) is a standard tool for detecting bone metastases.
• Early detection of bone marrow dissemination is crucial for prognosis and treatment planning.

Purpose of the Study:

• To evaluate the efficacy of bone marrow scintigraphy (BMS) in detecting skeletal invasion in breast cancer patients.
• To compare BMS with conventional bone scintigraphy (CBS) and other clinical data.
• To assess the prognostic implications of abnormal bone marrow findings.

Main Methods:

• Bone marrow scintigrams (BMS) were performed on 101 women with histologically confirmed breast cancer.
• BMS findings were compared with CBS, radiological, clinical, biological, and follow-up data.
• Skeletal metastasis was confirmed radiologically and/or histologically.

Main Results:

• Only 7.4% of patients with proven skeletal metastasis had normal BMS; 33 showed defects (BMS ++).
• Abnormal bone marrow extension was observed in 61.4% of patients, suggesting a reaction to disease dissemination.
• BMS detected skeletal invasion earlier or more precisely than CBS in ten cases.

Conclusions:

• Bone marrow scintigraphy (BMS) is a valuable tool for detecting skeletal invasion in breast cancer.
• Abnormal BMS findings correlate with disease dissemination and have prognostic significance.
• BMS offers advantages over CBS in early detection and precise assessment of bone involvement in breast cancer management.